-
Views
-
Cite
Cite
Geert Cauwenbergh, Piet De Doncker, Koen Stoops, Ann-Marie De Dier, Harry Goyvaerts, Viviane Schuermans, Itraconazole in the Treatment of Human Mycoses: Review of Three Years of Clinical Experience, Reviews of Infectious Diseases, Volume 9, Issue Supplement_1, January-February 1987, Pages S146–S152, https://doi.org/10.1093/clinids/9.Supplement_1.S146
- Share Icon Share
Abstract
During the first three years of clinical investigation of itraconazole, more than 1,000 patients with mycoses were treated with the drug. Almost 50010 were women with vaginal candidosis; a dosage of 200 mg per day for three days appeared to be optimal for their treatment. Several treatment regimens were tested for pityriasis versicolor; the minimum total dose necessary for optimal results was 1 g. A randomized comparison of 50-mg and l00-mg daily doses for the treatment of skin mycoses indicated that the optimal dosage is 100 mg. The results of short courses of treatment for superficial dermatophytoses suggest that such regimens may be effective, and the results of an ongoing double-blind comparison of itraconazole and griseofulvin suggest that itraconazole is superior in these infections. The outcome of treatment of systemic mycoses with itraconazole, especially sporotrichosis, chromomycosis, and aspergillosis, indicates that itraconazole may be useful in therapy for life-threatening fungal infections when standard therapy has failed.